STOCK TITAN

NUMINUS WELLNESS INC - NUMIF STOCK NEWS

Welcome to our dedicated page for NUMINUS WELLNESS news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on NUMINUS WELLNESS stock.

Numinus Wellness Inc. (NUMIF) is a mental health care company dedicated to advancing traditional and innovative behavioral health treatments through safe, evidence-based psychedelic-assisted therapies. They aim to heal rather than manage symptoms of depression, anxiety, trauma, pain, and substance use. By leading the integration of psychedelic-assisted therapies into mainstream clinical practice, Numinus is pioneering a healthier society. Numinus helps individuals heal and be well by providing innovative mental health care and access to safe, evidence-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.86%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
Rhea-AI Summary

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced participation in a Water Tower Research Fireside Chat on April 19, 2023, at 11:30 a.m. ET. The event will feature CEO Payton Nyquvest discussing key insights from the company’s fiscal Q2 2023 results, sector developments, and upcoming catalysts. Interested individuals can register here. Numinus focuses on innovative mental healthcare and psychedelic-assisted therapies aimed at treating mental health issues, establishing a foundation for a healthier society.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Summary

Numinus Wellness Inc. (TSX: NUMI) has launched a new client website as part of its branding strategy to unify its wellness clinics under one brand. The enhanced website aims to improve client experience with better navigation and appointment booking tools, fostering a supportive environment for those seeking mental health treatments. The site incorporates geo-location technology, reflecting available services in users' regions, especially amid varying timelines for regulatory approvals for MDMA and psilocybin-assisted therapies. This initiative aligns with Numinus's goal of expanding digital services and strengthening its platform for practitioner training and client support, ultimately driving growth in the psychedelic-assisted therapy sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.5%
Tags
none
Rhea-AI Summary

Numinus Wellness reported substantial financial growth in Q2 2023, with revenues soaring by 581.1% year-over-year to $5.4 million. Gross profit increased by 820.9% to $2.1 million, alongside a rise in gross margin to 39.3% from 29.1% in Q2 2022. Despite a slight sequential revenue decline of 5.5% due to seasonal impacts, the company's cash position remains robust at $19.7 million. The recent acquisition of Novamind contributed significantly to growth, and the firm is advancing a new licensing model to lower expansion costs. Numinus also plans to enhance its digital platforms for better practitioner training and client support, positioning itself as a leader in psychedelic-assisted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.5%
Tags
none
-
Rhea-AI Summary

Numinus Wellness has launched a new clinic licensing model called the Numinus Network, allowing independent practitioners to operate clinics under its brand. This model aims to reduce capital investment while expanding access to psychedelic-assisted therapies across North America. The company has partnered with Healing Commercial Real Estate Inc. to provide licensees with turn-key locations, enhancing operational support and clinic infrastructure. Numinus aims to advocate for more accessible treatment options, compelling practitioners to join their network while retaining independence. The licensing fees and investment costs will vary based on individual arrangements and locations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Summary

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will announce its Q2 2023 financial results on April 13, 2023, after market close. A conference call and webcast will follow at 5:30 p.m. Eastern time, where executives will discuss company performance and recent initiatives. Interested participants can register for the live webcast here. A replay will be available post-event until April 27, 2023. Numinus, focused on evidence-based psychedelic-assisted therapies, aims to transform mental health care by integrating these therapies into mainstream practice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
conferences
Rhea-AI Summary

Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) has launched the Numinus Certification Pathway, a comprehensive training program for psychedelic-assisted therapy (PAT). This initiative includes courses that develop core PAT skills through various teaching methods, ensuring practitioners gain competency in using psychedelic medications. Notably, over 200 practitioners have already participated in Numinus training since its inception in Fall 2022. The most sought-after course, The Fundamentals of Psychedelic-Assisted Therapy, begins its next intake in May 2023, emphasizing evidence-based care and safety. The program aims to enhance the quality of mental health services provided by trained professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none

FAQ

What is the current stock price of NUMINUS WELLNESS (NUMIF)?

The current stock price of NUMINUS WELLNESS (NUMIF) is $0.02605 as of December 24, 2024.

What is the market cap of NUMINUS WELLNESS (NUMIF)?

The market cap of NUMINUS WELLNESS (NUMIF) is approximately 10.9M.

What is Numinus Wellness Inc. focused on?

Numinus Wellness Inc. is dedicated to advancing mental health care through traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies.

What is Numinus Wellness Inc.'s mission?

Numinus Wellness Inc. aims to heal rather than manage symptoms for various mental health conditions such as depression, anxiety, trauma, pain, and substance use by integrating psychedelic-assisted therapies into mainstream clinical practice.

How does Numinus Wellness Inc. contribute to mental health care?

Numinus Wellness Inc. provides innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies, leading to healing and well-being for individuals.

What sets Numinus Wellness Inc. apart from other mental health care providers?

Numinus Wellness Inc. distinguishes itself by promoting healing through psychedelic-assisted therapies rather than symptom management, pioneering a healthier society.

What is the goal of Numinus Wellness Inc. in the mental health care space?

Numinus Wellness Inc. aims to integrate psychedelic-assisted therapies into mainstream clinical practice, transforming mental health care and building a foundation for a healthier society.

NUMINUS WELLNESS INC

OTC:NUMIF

NUMIF Rankings

NUMIF Stock Data

10.90M
309.90M
3.85%
2.67%
Medical Care Facilities
Healthcare
Link
United States of America
Vancouver